CSL

CSL Cash Flow per Share

The Operating Cash Flow per Share of CSL (CSL.AX) as of Sep 17, 2026 is 7.49 USD. In the previous year, Operating Cash Flow per Share was 7.33 USD — a change of 2.30% (higher).

Cash Flow per Share

7.49USD

YoY

2.30%

Last updated:

Operating Cash Flow per Share of CSL is 2026 7.49 USD. Operating Cash Flow per Share of CSL was 2025 7.33 USD. It decreases by 2.30% higher compared to the previous year.

The CSL Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
3.61 USD
Jan 1, 2020
7.90 USD
Jan 1, 2021
10.54 USD
Jan 1, 2022
7.87 USD
Jan 1, 2023
8.05 USD
Jan 1, 2024
5.69 USD
Jan 1, 2025
7.33 USD
Jan 1, 2026
7.49 USD
The CSL Cash Flow per Share history
YEARCash Flow per ShareYoY
7.49USD+2.30%
7.33USD+28.80%
5.69USD-29.36%
8.05USD+2.27%
7.87USD-25.32%
10.54USD+33.40%
7.90USD+118.89%
3.61USD-13.81%
4.19USD+52.54%
2.75USD+3.73%
2.65USD-10.07%
2.94USD-0.38%
2.96USD
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Operating Cash Flow per Share of CSL is 7.49 USD in 2026.

Operating Cash Flow per Share of CSL changed from 7.33 USD to 7.49 USD, representing a 2.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share CSL since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

Cash Flow — CSL

All Key Metrics — CSL